tbuckley/cabot-search huggingface dataset:
Concepts, Labeling Procedures, and Design of Cell Proliferation Studies Relating to Carcinogenesis
Authors: Thomas L. Goldsworthy, Byron E. Butterworth, Robert R. Maronpot
Journal: Environmental Health Perspectives (1993)

Chemicals may induce cell proliferation directly as mitogens or indirectly via cell death with subsequent proliferation to replace lost cells.Chemically induced proliferation has been demon- strated to play a role in the carcinogenic process.A wide range of procedures and techniques are currently being used to define the quantitative relationship between the extent and duration of chemically induced cell proliferation and carcinogenic potential in different species and target organs.However, a limited database and nonstandard protocols and procedures for measuring cell proliferation have made it difficult to compare results between laboratories.Comparison of frequencies of S phase between control and treated animals is the most commonly used end point in cell proliferation studies and may be regarded as an indirect indication of a prolifera- tive response.This response can be ascertained as labeling indexes (LI; percentage of cells in S phase) after the administration of the DNA precursor labels (tritiated thymidine; 3H-TdR; bromodeoxyuridine, BrdU) or through immunostaining of the endogenous cell replication marker, proliferating cell nuclear antigen (PCNA).Both approaches are applicable to tissue sections.An important issue in the design of experimental studies for measuring LI is determining how and when to investigate proliferative responses in relation to the chemical treatment regimen.Variables to consider when designing cell proliferation studies include the animal's age, chemical dose and method of treatment, choice and dose of label, time and length that the label is administered, and methods of quantitation.Study design considerations depend on the experi- mental objective.A common approach to characterize the complex relationship of cell prolifera- tion and carcinogenic activity has been to focus on relatively early (less than 90 days) prolifera- tive responses in the target tissue.However, a larger database on the duration and nature of the chemically induced proliferative response under bioassay conditions in the target cell popula- tion is required to more clearly establish the role of this end point in the cancer process.In addition, studies must also investigate mitogenic versus cytotoxic induction of cell proliferation in normal and preneoplastic cells and differential toxicity that may provide a preferential growth advantage to spontaneous or chemically induced intermediate or malignant cells.
PRIORITY IN USE OF ADHESIVE STRIPS FOR VARICOSE ULCERS OF THE LEG
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis
Authors: Philip A. Marsden, Qin Ning, Laisum S. Fung, Xioping Luo, Yue Chen, Michael Mendicino, Anand Ghanekar, Jeremy A. Scott, Teresa Miller, Camie W.Y. Chan, Mathew W.C. Chan, Wei He, Reginald M. Gorczynski, David R. Grant, David A. Clark, M. James Phillips, Gary A. Levy
Journal: Journal of Clinical Investigation (2003)

Fibrin deposition and thrombosis within the microvasculature is now appreciated to play a pivotal role in the hepatocellular injury observed in experimental and human viral hepatitis. Importantly, the pathways by which fibrin generation is elicited in viral hepatitis may be mechanistically distinct from the classical pathways of coagulation induced by mechanical trauma or bacterial lipopolysaccharide (LPS). In the setting of murine hepatitis virus strain-3 (MHV-3) infection, a member of the Coronaviridae, activated endothelial cells and macrophages express distinct cell-surface procoagulants, including a novel prothrombinase, Fgl2/fibroleukin, which are important for both the initiation and localization of fibrin deposition. To assess the role of Fgl2/fibroleukin in murine viral hepatitis we generated a Fgl2/fibroleukin–deficient mouse. Peritoneal macrophages isolated from Fgl2/fibroleukin–/– mice did not generate a procoagulant response when infected with MHV-3. Fibrin deposition and liver necrosis were markedly reduced, and survival was increased in mice infected with MHV-3. To address the relevance of Fgl2/fibroleukin in human chronic viral hepatitis we studied patients with minimal and marked chronic hepatitis B. We detected robust expression of Fgl2/fibroleukin mRNA transcripts and protein in liver tissue isolated from patients with marked chronic hepatitis B. Fibrin deposition was strongly associated with Fgl2/fibroleukin expression. Collectively, these data indicate a critical role for Fgl2/fibroleukin in the pathophysiology of experimental and human viral hepatitis.
Clinicopathological studies of a patient with adult T‐cell leukemia and pseudogynecomasty
Authors: Paula Loureiro, Sarka O. Southern, Peter J. Southern, Maria S. Pombo‐de‐Oliveira
Journal: American Journal of Hematology (2000)

We present a rare case of adult T cell leukemia/lymphoma (ATL) in which leukemic T cells expressed CD4 and CD25 surface antigens and infiltrated mammary glands during clinical course of the disease. A 40-year-old male was admitted with long-standing skin lesions and leukocytosis. Peripheral blood lymphocytes were highly pleomorphic and presented CD2, CD4, CD25, CD38 membrane surface antigens. The patient proved to be seropositive for human T-cell lymphotropic virus type I (HTLV-I) antibodies. Monoclonal expansion of lymphoid cells integrated with HTLV-I genome was observed, and the diagnosis of ATL chronic type was made. He underwent a chemotherapy regimen, and skin lesions and leukocytosis improved markedly. He progressed with an indolent clinical course of ATL, when he was admitted with bilateral hyperplasia of breast, recurrent skin lesions, and leukocytosis. Breast biopsy revealed bilateral gynecomasty, extensive leukemic infiltration of typical ATL cells in the mammary glands, and the presence of mammary epithelial cells productively infected with HTLV-I. This is the first report describing invasion of the mammary tissue with HTLV-I-transformed T-cells and HTLV-I-associated breast disease. Am. J. Hematol. 65:256–259, 2000. © 2000 Wiley-Liss Inc.
Lipoma, Not Lymphoma
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ascending Aortic Replacement With Aortic Valve Reimplantation
Authors: Wolfgang Harringer, Klaus Pethig, Christian Hagl, Gerd P. Meyer, Axel Haverich
Journal: Circulation (1999)

Background —Reimplantation of the native, structurally intact aortic valve within a Dacron tube graft in patients with aortic root aneurysms corrects annular ectasia and dilatation of the sinotubular junction. The durability of this valve repair with respect to the increased mechanical stress on valve cusps has been discussed, is quite controversial, and is yet unknown. Methods and Results —From July 1993 to November 1998, a replacement of the ascending aorta with a repair of the aortic valve was performed in 75 patients (53 men and 22 women aged 50±19 years). Twenty-one patients (28%) had Marfan syndrome, and 11 patients (15%) had an aortic dissection, type Stanford A (6 acute, 5 chronic). In 17 patients (23%), concomitant replacement of the aortic arch was necessary. Clinical and echocardiographic follow-up was performed in 6- to 12-month intervals for a cumulative study period of 137 patient-years. No operative deaths occurred. Two patients (3%) died 5 and 20 months postoperatively. One additional patient experienced a transient ischemic attack within the first postoperative week. Three patients (4%) with progressive aortic insufficiency required aortic valve replacement after 9, 11, and 14 months. All other patients had no or mild aortic insufficiency. The repairs have now remained stable for ≤65 months (mean, 22±20 months). Other valve-related complications did not occur. Conclusions —Our results demonstrate that this type of aortic valve repair achieves excellent results in selected patients. Perfect coaptation of valve cusps during the repair with no or only trace aortic insufficiency at initial echocardiography seems to be essential for durability.
<i>HFE</i> Genotype in Patients with Hemochromatosis and Other Liver Diseases
Authors: Gordon D. McLaren
Journal: Annals of Internal Medicine (2000)

Letters1 February 2000HFE Genotype in Patients with Hemochromatosis and Other Liver DiseasesGordon D. McLaren, MDGordon D. McLaren, MDUniversity of California, Irvine; Veterans Affairs Long Beach Healthcare System; Long Beach, CA 90822 (McLaren)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-3-200002010-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Bacon and colleagues' report (1) indicates that determination of HFE genotype in patients with liver disease and possible iron overload may lead to identification of unsuspected C282Y homozygotes. In an editorial, Franks and Burke (2) note that some of the homozygotes did not have an elevated hepatic iron index; they suggest that the authors are guilty of circular reasoning because the authors conclude that absence of this criterion does not exclude the C282Y homozygous state. This is exactly what the data show, however, and the relevant question is whether this finding reflects a lack of full disease ...References1. Bacon BR, Olynyk JK, Brunt EM, Britton RS, Wolff RK. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med. 1999;130:953-62. LinkGoogle Scholar2. Franks AL, Burke W. Will the real hemochromatosis please stand up? [Editorial]. Ann Intern Med. 1999;130:1018-9. LinkGoogle Scholar Author, Article, and Disclosure InformationAuthors: Gordon D. McLaren, MDAffiliations: University of California, Irvine; Veterans Affairs Long Beach Healthcare System; Long Beach, CA 90822 (McLaren) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoWill the Real Hemochromatosis Please Stand Up? Adele L. Franks and Wylie Burke HFE Genotype in Patients with Hemochromatosis and Other Liver Diseases Bruce R. Bacon , John K. Olynyk , Elizabeth M. Brunt , Robert S. Britton , and Roger K. Wolff HFE Genotype in Patients with Hemochromatosis and Other Liver Diseases Lawrie W. Powell HFE Genotype in Patients with Hemochromatosis and Other Liver Diseases Bruce R. Bacon , Robert S. Britton , and John K. Olynyk HFE Genotype in Patients with Hemochromatosis and Other Liver Diseases Adele L. Franks and Wylie Burke Metrics 1 February 2000Volume 132, Issue 3Page: 245KeywordsAlgorithmsGenetic testingHemochromatosisLiverLiver diseasesMutationPhlebotomyReasoning ePublished: 15 August 2000 Issue Published: 1 February 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Carcinogenic Risk Assessment: Comparison of Estimated Safe Doses for Rats and Mice
Authors: James J. Chen, David W. Gaylor
Journal: Environmental Health Perspectives (1987)

Data from the National Cancer Institute/National Toxicology Program (NCI/NTP) carcinogenesis bioassays were examined to compare cancer risks in rats and mice. Only those bioassays where chemicals were administered orally were used. The ratios for rats to mice of the virtually safe dose (VSD) levels associated with a risk of 10(-6) were compared. Comparisons of the ratios were made for those chemicals that NCI/NTP determined to be carcinogenic in at least one species and that showed a dose response trend in the same sex at the same tissue/organ site in the other species. In all, 69 comparisons from 38 carcinogens were performed. The overall geometric mean of the VSD ratios is 1.27 in terms of concentration (ppm); the mean and the standard deviation in logarithm are 0.24 and 1.83, respectively. The VSD ratios vary from 1:51 to 49:1. Without the restriction of the same sex and site, the geometric mean of the minimum VSDs is 1.38, and the standard deviation in logarithm is 1.79. By directly comparing the VSDs for rats and mice (as they are performed for risk assessment), this study showed a probability of 0.10 that the ratio of VSDs is greater than 10, and the ratio is greater than 20 with a probability of 0.05 when a chemical is carcinogenic in both species.
Consultations
Authors: ALEX M. BURGESS
Journal: Annals of Internal Medicine (1961)

Editorials1 October 1961ConsultationsALEX M. BURGESS, M.D., F.A.C.P.ALEX M. BURGESS, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-55-4-698 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptWhen thou arte callde at anye time, A patient to see; And doste perceave the cure too grate, And ponderous for thee:See that thou laye disdeyne aside, And pride of thyne owne skyll: And thinke no shame counsell to take, But rather wyth good wyll.Gette one or two of experte men, To help thee in that nede: And make them partakers wyth thee, In that worke to procede.. . . . But one thing note, when two or moe Together joyned be; Aboute the paynfull patient, See that ye doe agree.See that no discorde doe arise... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: 107 Bowen Street, Providence 6, Rhode Island PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 October 1961Volume 55, Issue 4Page: 698-702 ePublished: 1 December 2008 Issue Published: 1 October 1961 PDF downloadLoading ...
Chronic Pyelonephritis: Morphologic-Bacteriological Study
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
"Geriatric emergencies"
Authors: W. Fine
Journal: BMJ (1967)

<b>Introduction:</b> One in ten people recovering from COVID-19 experience prolonged symptoms (&gt;12 weeks), with many reporting breathlessness more than a year after acute infection. There is an urgent need to understand the recovery from COVID-19 and to identify safe, effective rehabilitative strategies. <b>Aims:</b> To investigate the recovery from COVID-19 and the potential rehabilitative role of inspiratory muscle training (IMT). <b>Methods:</b> 250 adults (48±16 yrs; 84% female) recovering from self-reported COVID-19, with a primary symptom of shortness of breath, were randomised 4:1 to an 8-week IMT or control arm, respectively. Breathlessness (King’s Brief Interstitial Lung Disease (KBILD) Questionnaire), respiratory muscle strength, fitness (Chester Step Test) and device-based physical activity (PA) were assessed at baseline and post-intervention. <b>Results:</b> In the first 87 participants (68 IMT) completed to date, IMT improved all domains of the KBILD, with breathlessness reduced by 33% (P&lt;.001) - twice the minimal clinically important difference. Furthermore, IMT improved maximal inspiratory pressure (MIP; baseline 75±32 vs. post 117±58 cmH2O; P&lt;.001), sustained MIP (420±204 vs. 575±265 PTUs; P&lt;.001), fatigue index (17±12 vs. 23±16 au; P&lt;.001) and fitness (36±13 vs. 44±19 ml·kg-1·min-1; P&lt;.001). PA was unchanged. Time was associated with non-significant improvements in all parameters, but the magnitude of improvement was 2–14 times greater with IMT. <b>Conclusions:</b> IMT significantly accelerated the rate of recovery from COVID-19 and represents an acceptable and feasible home-based rehabilitation tool that should be considered for wider implementation as part of COVID-19 recovery strategies.
Journal of Pediatrics, St. Louis
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Analysis of Total Serum Cholesterol by Gas-Liquid Chromatography
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
T-lymphocyte subsets in lymph nodes from homosexual men
Authors: R. L. Modlin
Journal: JAMA (1983)

To evaluate further the immunodeficiency of homosexual men, blood and lymph node specimens were obtained from five homosexual men with lymphadenopathy and from seven homosexual men with Kaposi's sarcoma. Monoclonal antibodies were used to identify T-lymphocyte subsets in blood by cytofluorometry and in frozen sections of nodes by immunoperoxidase techniques. The homosexuals with Kaposi's sarcoma had a T-helper/ suppressor ratio in blood of 0.7; the homosexuals with lymphadenopathy had a ratio of 0.6, compared with controls of 2.1. Control lymphoid tissue had a ratio of 3.0 in the interfollicular areas compared with the reactive lymph nodes in the homosexuals with lymphadenopathy, which was 0.7, and nodes from patients with Kaposi's sarcoma, 0.9. The nodes from homosexual men had evident numerous suppressor cells in the follicular center and mantle regions, locations in normal lymphoid tissue where suppressor cells were uncommon. (<i>JAMA</i>1983;250:1302-1305)